Formulary guidance and transparency from P&T to point of care


Reality Check on Bipolar Disorder

Market access for bipolar disorder treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 43% of the lives under commercial and Medicare formularies are covered with utilization management restrictions
  • Class Trends: In May 2019, the FDA approved Allergan's Vraylar for the depressive form of bipolar I disorder, making it the first drug approved to treat the full spectrum of bipolar I symptoms
  • Key Findings: The market contains multiple strong oral generics. Competition amongest brand name products after failure of oral generics is expected 

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.